CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened

• On March 3, 2026, Cumberland Pharmaceuticals Inc. announced and filed a Current Report on Form 8-K (Item 2.02) disclosing a company update and its financial results for the three months and fiscal year ended December 31, 2025.
• The company attached a press release dated March 3, 2026 as Exhibit 99.1 to the 8-K. The report was signed by Chief Financial Officer John Hamm.

Key Details

• Filing date: March 3, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: three months and year ended December 31, 2025.
• Press release attached as Exhibit 99.1 contains the full financial results and company update.
• Report was executed by John Hamm, CFO, under the Section 9.01 exhibit filing.

Why It Matters

• This 8-K announces that Cumberland’s latest quarterly and full-year earnings and related financial details are now public; investors should review the attached press release for revenue, earnings, cash position, and any management commentary.
• The filing alerts the market to new earnings information that may affect short-term trading and investor assessments of the company’s performance and outlook.